Сумамед

Основна информация

  • Търговско наименование:
  • Сумамед форте сироп 200 mg/5ml прах за перорална суспензия - 15ml; 30ml; 37.5ml
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Сумамед форте сироп 200 mg/5ml прах за перорална суспензия - 15ml; 30ml; 37.5ml
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Sumamed Forte Syrup, 200 mg/5ml powder for oral suspension - 15ml; 30ml; 37.5ml

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20010176
  • Дата Оторизация:
  • 07-10-2015
  • Последна актуализация:
  • 01-06-2018

Листовка за пациента

13-8-2018

Health Canada Warns Canadians of New Safety Information Related to Long-Term Use of Azithromycin Following Stem Cell Transplants in Cancer Treatment

Health Canada Warns Canadians of New Safety Information Related to Long-Term Use of Azithromycin Following Stem Cell Transplants in Cancer Treatment

OTTAWA – Health Canada is warning Canadians of the potential risk of cancer relapse in patients with cancer of the blood and lymph nodes who have undergone stem cell transplant and are taking long-term azithromycin (Zithromax).

Health Canada

3-8-2018

Zithromax, Zmax (azithromycin): FDA Warning - Increased Risk of Cancer Relapse With Long-Term Use After Donor Stem Cell Transplant

Zithromax, Zmax (azithromycin): FDA Warning - Increased Risk of Cancer Relapse With Long-Term Use After Donor Stem Cell Transplant

The antibiotic Zithromax, Zmax (azithromycin) should not be given long-term to prevent a certain inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant. Results of a clinical trial found an increased rate of relapse in cancers affecting the blood and lymph nodes, including death, in these patients.

FDA - U.S. Food and Drug Administration

Няма новини за този продукт.